Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)

NCT04125290 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04125290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04125290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Terminated
Start date
December 9, 2019
Completion date
June 21, 2021
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hairy cell leukemia